<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 319 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page318.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=319">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 319 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 319</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=319"><img src="../thumb/319.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>282 / 2020-04                                                            Anti-Microbials - 18.12
   (S4) TABS. 42/20.2.8/0001    Contraindications: Pregn., lactat., mod-sev.ren. impairm., concur.  Warnings and special precautions: Monit. hepat.funct.for sev.
   716427-001: 60, R599,48      astemizole/bepridil/cisapride/ ergot derivat./midazolam/pimozide /  mnths.in pts.co-infect.with HIV & HBV who discont.ther.& appropr.
   Dosage: Adults & childr.over 12 yrs: Init.2 wk. lead.in treatm.  triazolam & voriconazole, safety & effic. not est.in HBV & HIV co-  init.of anti-hepatit. B ther.poss.necess., obesity & prolong. nucleo-
   period on the 3 indiv. compon.to be complet.as follows: Lamivudine   infects., concom.lamivudine/meds.contain. lamivudine in combinat.,   side use poss.risk fact.for lact.acidos., liv. dis.risk fact., discont.if
   300 mg once dly.or 150 mg 2xdly. Zidovudine 300 mg 2xdly. Nevirap-  concom.St Johns Wort not recomm., not recom.in pts.less than 18   find.suggest.lact.acidos. /hepatotoxic., test for chron.hepatit.B bef.
   ine 200 mg once dly. Follow.lead in period & in absence of any hy-  yrs., concom.atazanavir not recomm.  init.ther., monit. for it.exacerbat.if treatm.discont.in HIV & HBV co-
   persens./GI reacts carry out dos.escalat.to 200 mg Nevirapine 2xdly.  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.  infect.pts., treatm.discont.poss.reqd.if ser. psych. sympt.exper., de-
   Recomm.dos: 1 tab.2xdly.     fatal.esp.in women, sev.ac. exacerbat. of hepatit.B aft.discontinuat.  term.creatin.clear.bef.init. & dur.ther., ren.funct.monit.in pts.at risk/
   Contraindications: Abnorm.low neutrophil counts /haemoglobin   of emtricitabine/ tenofovir, ser.CNS & psych.sympts., alt. coagulat.  hist.of ren.dysfunct., avoid with concom./rec.nephrotox. agents,
   lev., safety & effic.in childr. und. 12 yrs.not est., safety in pregn.&   times, poss.birth defects, sinusit., URTI, nasopharangit., neutro-  elderly, high.freq.adverse events with efavirenz/ ritonavir, monit.
   lactat.not est., concom.ribavirin/stavudine, sev.hepat. dysfunct.,   pen., anaem., immune reconstitut. syndr., nephrogen.diabet.insipid.,   liv.enzym.with efavirenz/ ritonavir, do not admin.concom. saqui-
   Child-Pugh class B or C, end-stage ren. fail. in pts.not on haemodi-  Cushingoid appear., redistribut./accumulat.of body fat, GI disturbs.&   navir as sole protease inhibit., reg. carbamazepine lev.monit.with
   alys., pre-treatm./dur. treatm. values of AST/ALT&gt; 5x ULN until AST/  malabsorpt., aggress., suicid. thoughts/ attempts, imp.conc., insom.,   concom.use, altern. anticonvuls. agent advis., Ca chann.blocks.
   ALT stabilis. &lt; 5x ULN., re-admin.where ther.perman. discont. for sev.  amnes., anx., depress., abnorm.think./dreams, mania, somnolence,   dos. adjustm. guid.by clinic.respons., women of child-bear. potent.
   rash/rash with constitut.sympts./ hypersens. syndr./clinic.hepatit.,   headache, asthen., dizzin., hypoaesthes., convuls., paraesthes., pe-  should undergo pregn.test.bef. init. ther., barr.contracept.tog.with
   AST/ALT values &gt; 5x ULN dur. ther.& had rapid recurr.of liv.funct.   riph. neuropathy, tinnit., dyspn. cough, rhinit., pneum., pancreatit.,   other methods recomm., pt.on treatm.may devel.opportunist. in-
   abnormalit. on re-admin., concom.ketoconazole & St. John’s Wort,   rais.liv.enzym., hepat. fail., hepatotox., arthralg., myalg., myopathy,   fect./ other HIV infect.compl., contin.approp. precaut. prevent.HIV
   IV ganciclovir/foscarnet not recomm.  back-/bone pain, osteomalac., nephrit., ac.ren.fail., Fanconi syndr.,   transmiss.risk, investig. child. expos.in utero to nucleoside & nucleo-
   Side effects: Sev.& life threaten.skin reacts.incl. Stev.-John.& tox.  proxim. ren.tubulopathy, ac.tubul.necros., breast enlargem., fatig.,   tide analog. for poss.mitochondr.dysfunct.in case of relev.S&S, liv.
   epiderm.necrolys., hypersens. syndr.charact.by constitut.finds.&   rais.ser.cholestrol & triglycer. conc., hyperglyceridaem., allerg.re-  enzym.monit.in pts.with mild to mod.liv.dis & chron. hepatit.B or C,
   visceral involvem., sev.& life threaten.hepatotox.incl.fatal fulmin.  acts., gynaecomast., hypophosphataem., abnorm.vis., palpitat.,   seiz/psych.disord.hist., discont.t her.with sev.skin rash assoc.with
   hepatit.& hepat.fail., anaem., neutropen., leucopen., pancreatit.,   prurit., rash, erythem.multiforme/nail disords./ Stev.-John.syndr.,   blister./ desquamat./mucos.involvem.& fev., monit.ser. lipids & bld.
   lact.acidos.in absence of hypoxaem.& sev. hepatomegaly with   photo allerg.dermatit., skin discol.  gluc., bone monit.with bone fract. hist./ risk of osteopen., discont.if
   steatos., periph.-/ facial wast., redistribut./accumulat.of body   Special precautions: Monit.hepat.funct.for sev. mnths. in pts.  rapid incr.in aminotransfer. conc.occ.
   fat.(buffalo hump), granulocytopen., allerg. reacts. incl.anaphylax.,   co-infect.with HIV & HBV who discont. ther.& appropr.init.of anti-  Drug interactions: Reduc.NNRTI conc.with St John’s Wort expect.,
   headache, GI disturbs., myalg., arthralg., fatig., fev., thrombocyto-  hepatit.B ther. poss.necess., obesity & prolong.nucleoside use   addit.CNS effs.with alcoh./ psychoact. meds., alt.plasma conc.of
   pen., hyperlacticaem., insomn., paraesthes., periph. neuropathy,   poss. risk fact.for lact.acidos., liv.dis.risk fact., discont. if find.  meds.prim. metab. by cytochrome P450 isoenzym., rifampicin decr.
   nas.sympts., cough, alopec., musc.-skelet. pain, rhabdomyolys.,   suggest.lact.acidos./hepatotoxic., test for chron.hepatit.B bef.  efavirenz conc., clarithromyc.plasma lev. decr., efavirenz reduc.vori-
   pancytopen., ment. acuity loss, somnol., anx., depress., convuls.,   init.ther., monit.for hepatit.exacerbat.if treatm.discont.in HIV &   conazole plasma conc.& vice versa, amprenavir./fosamprenavir/
   taste pervers., cardiomyopathy, dyspn., oral mucosa/nail & skin   HBV co-infect.pts., eval.psych.adver.exper.if relat.to efavirenz   atazanavir/ indinavir/lopinavir & saquinavir ser.conc decr., efavirenz
   pigmentat., myopathy, urin.freq., gynaecomast., flu-like syndr.,   use, nerv.syst.sympts.poss.abate aft.2-4 wks., determ. creatin.  metabol.inhibit.by grapefruit juice, conc. of drugs reduc.ren.funct./
   chills, gen/chest pain.      clear.bef.init.& dur.ther., ren. funct.monit.in pts.at risk/hist.of ren.  elimin.by act.tubul. secret. may be incr., atazanavir & lopinavir/ ri-
             st
   Special precautions: 1  18 wks.ther.critic.to monit.for sev.& life-  dysfunct., avoid with concom./rec.nephrotox.agents, elderly, monit.   tonavir incr.tenofovir conc., reduc.anticonvuls. &/efavirenz.plasma
   threat.skin reacts.& ser. hepatit. /hepat.fail., great.risk of hepat.  concom.didanosine, high.freq.adverse events with efavirenz/rito-  lev.with carbamazepine/ phenytoin & phenobarbit., sertraline conc.
              st
                         +
   events & skin reacts.occur.1  6 wks.ther., women CD4  &gt;250 & men   navir, monit.liv.enzym. with efavirenz/ritonavir, do not admin.con-  decr., HMG-CoA reduct.inhibit./indinavir/itraconazole conc. decr.,
   CD4  &gt; 400 counts at incr.risk hepat. adverse events, dos.esp.14   com. saquinavir as sole protease inhibit., monit.INR with warfar.,   potent.decr.ketoconazole conc., rifabutin conc.decr., plasma conc.
     +
   day lead in period to be strict. adher.to, perman.discont.ther.in pts.  monit.anticonvuls.plasma lev., Ca chann. blocks.dos.adjustm.guid.  of other compds. that are CYP3A4 substrat.poss.decr., poss.Ca
   exper. sev. rash/rash with constitut.sympts./in case of hypersens.  by clinic.respons., teratogen. in anim., women of child-bear.potent.   chan. block. conc.decr., decr.methadone plasma conc.& poss. opi-
   syndr.& visceral involvem., perman. discont. ther.in pts.with mod.to   should undergo pregn.test.bef.init.ther., barr. contracept. tog.with   ate withdr.signs with efavirenz, ethinyl oestrad. conc.incr., warfar.
   sev.elev.(AST/ALT &gt;5 x ULN), incr.AST/ALT lev.and/or chron.hepatit.   other methods recomm., pt.on treatm.may devel.opportunist.in-  plasma.conc.potent. incr./decr.
   B&C co-infect.prior to ther.is assoc.with great.risk of hepat. adverse   fect./other HIV infect. compl., contin.approp.precaut.prevent.HIV   TRUVADA, (Aspen Pharmacare: Pharma) Pharmacare P/S]
   events, freq.monit.of pts with AST/ALT of 2,5x ULN bef./dur.early   transmiss.risk, investig.child.expos.in utero to nucleoside & nucleo-  Emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg
   treatm.period for developm.clinic./lab.evid.of liv.funct. deteriorat.,   tide analog.for poss. mitochondr. dysfunct.in case of relev.S&S,   Indications: In combinat.with other antiretrovir. in adults with HIV-
   risk fact.for develop.ser.cutan.reacts. incl. fail.to foll.lead-in period   discont. ther. with sev.skin rash assoc.with blister./ desquamat./   1, pre-expos. prophylax. (PrEP) in combinat.with safer sex practic.in
   dos., ther.assoc.rash perform liv.funct.test.immed., long delay betw.  mucos.involvem.& fev., liv.enzym. monit. in pts.with mild to mod.  prov.HIV-1 uninfect. adults to red. risk of sexual.acquir. HIV-1 in pts.
   init. sympts.& medic.consult.may incr.risk of more ser. cutan. reacts.,   liv.dis & chron. hepatit.B or C, bone monit.with bone fract.hist./   at high risk prov.complianc.monit.
   concom.antivir.ther.for hepatit.B & C refer relev.medic.product info of   risk of osteopen.with Vit.D & Ca supplementat.  (S4) TABS, 41/20.2.8/0171
   products, women at high.risk than men of rash assoc. hepat. events   Drug interactions: Reduc.NNRTI conc.with St John’s Wort expect.,   708254-001: 30, R674,54
   dev., monit.liv.funct.prior to & at interv.dur. ther., monit.haematolog.  addit.CNS effs.with alcoh./ psychoact. meds., efavirenz reduc.vori-  Dosage: 1 tab.once dly.without regard to food.
   paramet., in case of sev. anaem./myelosuppress./pre-exist.bone   conazole plasma conc., alt.plasma conc.of meds.prim. metab. by   Contraindications: Safety & effic.not est.in hepatit. B vir.co-in-
   marrow compromise where dos. adjustm.may be reqd./ where dis-  cytochrome P450 isoenzym., conc.of drugs reduc.ren.funct./elimin.  fects., mod.to sev.ren.impairm., creatin.clear. &lt; 60 ml/min when
   cont.of one of the act.necess.use separ. preps., discont.use if pan-  by act.tubul.secret. may be incr., poss.incr.didanosine plasma conc.,   used for PrEP & &lt; 50 ml/min when used for treatm.of HIV-1., pregn.
   creat.suspect., suspend.if aminotransferase lev.are rapidly elevat/  atazanavir & lopinavir/ritonavir incr.tenofovir conc., amprenavir./  & lactat., concom.drugs contain lamivudine/ tenofovir/emtricitabine,
   progress. hepatomeg/metabol.or lact.acidos.devel., opportunist.   atazanavir/indinavir/lopinavir & saquinavir ser.conc decr., high.  safety & effic.in paed.pts. not est., PrEP in indiv.not fully committ.to
   infects.& other complicat.of HIV infect. may contin., HIV transmiss.  didanosine conc., warfar. conc.incr.&decr., reduc.anticonvuls.&/ efa-  treatm. compl./indiv.with unknown/ posit. HIV-1 status
   not prev.by ther., concom.flucoconazole/warfar./co-trimoxazole/   virenz. plasma lev.with carbamazepine/ phenytoin & phenobarbit.,   Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.
   phenytoin, alt.ther.to clarithromycin recom.in Mycobacterium avi-  sertraline/rifabutin/ diltiazem/HMG-CoA reduct.inhibit./indinavir/   incl.fatal., sev.ac.exacerbat.of hepatit. B aft.discontinuat., head-
   um-intracellular complex., altern. non-hormon.contracept.recomm.,   itraconazole conc.decr., potent.decr.ketoconazole conc., clarithro-  ache, asthen., dizzin., periph.neuropathy, GI disturbs., rash, myalg.,
   monit. methadone maint.pts.as narcot.withdr.syndr. report., monit.  myc.plasma lev.decr., rifampicin decr. efavirenz conc., poss.Ca chan.  neutropen., anaem., hyperbilirubinaem., hypertriglyceridaem., hy-
   concom.potent.nephrotox./ myelosuppress. meds., dos.escalat.not   block.conc. decr., decr.methadone plasma conc.& poss.opiate withdr.   perglycaem., pancreatit., abdom. pain, insomn./abnorm.dreams,
   allow.if rash occur.dur lead-in dos.until rash.resolv., if ther. interrupt.  signs with efavirenz, ethinyl oestradiol conc. incr.  dyspn., hepatit., hepat.steatos., hypophosphataem., hypokalaem.,
   for long.than 7 days restart accord.to lead-in dos.regime using in-  See also MDR page 112.  ren.impairm.incl. ac.ren.fail., Fanconi syndr., proxim.tubulopathy,
   div.meds., separate preps. to be admin.in ren./sev.hepat.impairm.&   nephrogen. diabet. insipid., proteinur., ac.tubul.necros., polyur., in-
   when haematologic.effs.report., elderly, concom. paracet.& low ser.  TRUNO, (Activo) Aurobindo [P/S]  terstit. nephrit., allerg.reacts.incl.angioed., BMD decr. from baseline,
   vit.B 12 lev.poss.incr.neutropen. incid., advanc.liv.cirrhos.as a result of   Efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil fu-  osteomalac., osteonecros., body fat redistribut./accumulat., incr.liv.
   chron. hepatit. B infect.as low risk of rebound hepatit. poss.if lami-  marate 300 mg.  enzym., creat. kinase elev., myopathy
   vud.stopp., supplem.nevirapine treatm. in ren.dysfunct.pts.undergo.  Indications: HIV-1 infect.treatm.in adults alone as complete regi-  Warnings and special precautions: Not recomm. as part of tri-
   haemodialys.with addit. 200 mg nevirapine dos.follow.each haemo-  men or in combin.with other anti-retrovir.  ple nucleoside regim., obesity & prolong. nucleoside use poss.risk
   dialys. treatm.to offset the haemodialys. eff.on nevirapine clear., pts.  (S4) TABS, 47/20.2.8/0572  fact.for lact.acidos., liv.dis.risk fact., pancreatit., mitochondr. dys-
   to report other meds. used to Dr.  720853-001: 30, R466,00  funct., discont.if find.suggest. lact. acidos./ hepatotoxic., test for
   Drug interactions: Low.plasma conc.of concom. meds. metabol.  Dosage: Adults: 1 tab.once dly.on empty stomach. Bedt.dos.may   hepatit.B bef. init. ther., monit.hepat.funct.xsev.mnths.if discont. &
   by CYP3A or CYP2B enzymes, saquinavir (hard gelatine caps) & in-  improv.CNS sympt. tolerabil.  pts. co-infect.with HIV & HBV, hepatitis C co-infect., imp.ren.funct.,
   dinavir AUC lev. reduc., AUC & C max of ketoconazole signif. reduc.   Contraindications: Concur.astemizole/bepridil/ cisapride/ mida-  concom./rec.nephrotox. meds., eval.poss.cause of decr.creatin.clear.
   & nevirapine plasma lev.incr., fluconazole incr. nevirapine expos.  zolam/pimozide/triazolam/ergot derivat.& voriconazole, mod-sev.  in uninfect.PrEP pts.and re-eval.risk-benef., concom. didanosine &
   by 100%, warfar may incr./ decr. coagulat.time, AUC/C max & C min of   ren.impairm., safety & effic. not est.in HBV & HIV co-infects., con-  discont.if advers.effs.develop, recom. concom. atazanavir be admin.
   nevirapine signific. low.by rifampicin, rifabutin conc.signific. incr.,   com. lamivudine/meds.contain.lamivudine in combinat., concom.  with ritonavir, monit. BMD in pts.with patholog.bone fract.hist./at
   nevirapine clear.incr.by rifabutin, hypericum perfortum (St John’s   St Johns Wort not recomm., safety & effic.in pts.less than 18 yrs.  risk of osteopen., pts.to report joint ache/pain/stiffn.& diffic. movem.
   Wort) decr.NNRTI’s conc.& result. sub-optimal lev., nevirapine trough   not est., concom. atazanavir/saquinavir not recomm., pregn., lac-  as osteonecros.poss., elderly., CV risk assessm. in pts.with evid.of
   conc. elev. with cimetidine, oestrog.lev.of OC’s signific. decr., plasma   tat., sev.hepat.impairm.  lipodystroph., immune reconstitut. inflammat.syndr., opportunist.
   conc.of methadone decr., lamivudine expos. incr.by prophylact.co-  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.  infects.& HIV complicat.may contin., does not prev. risk of HIV-1
   trimoxazole, zidovudine metabol.poss.modif.by codeine/morph./  fatal.esp.in women, sev.ac. exacerbat. of hepatit.B aft.discont.of   transmiss.to others, PrEP only as part of comprehens.prevent.strat-
   aspir./ indomethac./ketoprof./naprox./cimetid./clofibr./dapsone/  emtricitabine/ tenofovir, ser.CNS & psych.sympts., poss. birth de-  egy that include.other prevent. meas., PrEP only in indiv. confirm.HIV-
   oxazep./lorazep.& isoprinosine, zidovudine advers.event risk incr.  fects, pancreatit., rais.ser.cholestrol & triglycer.conc., sev.depress.,   neg. as TRUVADA alone does not constit.a compl. treatm. regim.for
   with potent.nephrotox/ myelosuppress.meds., ribavirin/stavudine   suicid.ideat./ attempts, amnes., aggress., mania, tinnit., palpi-  HIV-1, eval. seronegat.indivs.for curr./ rec. S&S consist.with ac.vir
   is antagonist.in vitro, probenecid incr.mean half-life & area und.  tat., dyspn., GI disturbs., rais.liv.enzym., hepat. fail., rash, prurit.,   infect. & enquire regard. poss expos.events in last mnth,if clinic.
   plasma conc.curve of zidovudine.  erythem.multiforme/nail disords./Stev.-John.syndr., photo allerg.  sympts. consist. with ac.vir.infect.pres.& recent vir. expos. suspect.
                                dermatit., skin discol., arthralg., myalg., myopathy, fatig., asthen.,   delay start. PrEP for at least 1 mnth & reconfirm HIV-1 status., rep.
   TRIVENZ, AI Pharm [P/S] &    pneum., neutropen., anaem., hyperbilirubinaem., abnorm.dreams,   HIV-1 screen.at least every 3 mnths.dur.PrEP treatm., monit.pts.on
   Efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil fu-  headache, asthen., dizzin., insom., anx., paraesthes., periph. neu-  ther. utilis. a triple nucleoside-only regim.caref.for early virolog.
   marate 300 mg.               ropathy, rhinit., pain, hypophosphataem., bone pain, osteomalac.,   fail./resist., lact.intol.
   Indications: HIV-1 infect.treatm.in adults alone as complete regi-  nephrit., nephrogen.diabet. insipid., ren.proxim.tubul.eff.incl.Fanconi   Drug interactions: Ser.conc.of drugs elimin.by act.tubul.secret.may
   men or in combination with other anti-retrovir.  syndr.& ac. tubul.necros., ac.ren.fail., sinusit., URTI, nasopharangit.,   incr., ser.conc.incr.by agents decr.ren.funct., C max & AUC of didanosine
   (S4) TABS, 47/20.2.8/0328    immune reconstitut.syndr., Cushingoid appear., redistrib./accumulat.  incr., AUC & C min of atazanavir decr.
   718672-001: 30, R306,33      of body fat, hyperglyceridaem., insul.resist., breast enlargem., pe-
   Dosage: Adults: 1 tab.once dly.on empty stomach. Bedt.dos.may   riph.& fac.wast., hyperton., myosit., rhabdomyolys., osteonecros.,   TYRICTEN, Novagen [P/S]
   improv.CNS sympt. tolerabil.  osteomalac., reduc. bone density.  Emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page318.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page314.html">314</a>&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>&nbsp;&nbsp;&nbsp;<a href="page321.html">321</a>&nbsp;&nbsp;&nbsp;<a href="page322.html">322</a>&nbsp;&nbsp;&nbsp;<a href="page323.html">323</a>&nbsp;&nbsp;&nbsp;<a href="page324.html">324</a>
             </td>
             <td width="35%"><a href="page320.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page320.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
